First in Human Trial of TAS266 in Patients With Advanced Solid Tumors

• Status: Terminated
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess safety, tolerability, maximum tolerated dose or recommended dose for expansion of TAS266 administered by IV infusion to patients with advanced solid tumors.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals

Criteria

Inclusion Criteria:

• Confirmed diagnosis of solid tumors

• 18 years or older

• ECOG performance status of 0, 1 or 2

• Adequate bone marrow, hepatic and renal function

• Obtained written informed consent

Exclusion Criteria:

• Patients with primary CNS tumor or CNS tumor involvement. However patients with CNS metastases may be allowed if certain conditions are met.

• Major surgery within 4 weeks before study treatment

• Prior anaphylactic or other severe infusion reactions to human immunoglobulin or antibody formulations

• Impaired cardiac functions

• Previous hepatitis viral infection such as hepatitis B or hepatitis C

• Diagnosis of HIV infection

• Pregnant or nursing (lactating) women

Other protocol-defined inclusion/exclusion criteria may apply